Ozempic Hair, GLP-1 Kids, Gut-Brain Anxiety, Food Additives, Taurine, and more

Podcast: The Human Upgrade: Biohacking for Longevity & Performance · Dave Asprey

Opublikowano: 2026-09-25

Novo Nordisk Eyes Hair-Loss Market in Consumer-Health Expansion Novo Nordisk, the company behind Ozempic and Wegovy, is exploring hair loss as one of several possible areas for future expansion, alongside menopause and addiction. The company has not announced a hair-loss drug, clinical trial, acquisition, or partnership, but Chief Scientific Officer Martin Holst Lange pointed to the category during the company's 2026 Capital Markets Day. Host Dave Asprey breaks down why hair loss makes strategic sense for a company already deeply involved in endocrine biology, how emerging treatments are moving beyond traditional options like minoxidil and finasteride, and why s...